A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
News|Articles|May 20, 2026
What Patients Should Look Forward to at ASCO 2026
Author(s)Spencer Feldman
Fact checked by: CURE staff
ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.
Advertisement
Advertisement
Dr. Josh K. Sabari, a thoracic medical oncologist at NYU Langone’s Perlmutter Cancer Center and editor-in-chief of CURE, discussed the most anticipated lung cancer data expected at the 2026 ASCO Annual Meeting in an interview with CURE, highlighting biomarker-driven care, targeted therapies and expanding treatment modalities across solid tumors.
Related to this article
Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.
A phase 3 trial found that adding Imdelltra to Imfinzi maintenance improved survival in extensive-stage small cell lung cancer, while another drug's application was pulled. Here's what patients should know.
Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.
September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.
Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.
Learn how to cope with life after cancer treatment with Dr. Eric Bengtsen, a psycho-oncology psychiatrist at Memorial Sloan Kettering Cancer Center.
A breast surgeon explains how rebuilding the breast with a person's own tissue and new tools may boost satisfaction and cut repeat surgery.
Advertisement
Advertisement